IP Library Granted Patent US 9,994,846
Granted Patent B2
US 9,994,846 · App. 15/029,535 · Granted Jun 12, 2018

MicroRNA compounds and methods for modulating miR-21 activity

Inventor: Balkrishen Bhat (Cambridge, MA)
Assignee: Regulus Therapeutics Inc.
C12N15/113C12N2310/113C12N2310/315C12N2310/3231C12N2310/343C12N2310/351C12N2310/3521C12N2310/3525
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,994,846
App. No.
15/029,535
Granted
Jun 12, 2018
Kind
B2
Abstract

Described herein are compositions and methods for the inhibition of miR-21 activity. The compositions have certain nucleoside modifications that yield potent inhibitors of miR-21 activity. The compounds may comprise conjugates to facilitate delivery to the liver. The compositions may be administered to subjects with liver conditions, such as liver cancer.

Claims (8)

1. A method of inhibiting the proliferation of a liver cancer cell, comprising contacting the cell with a compound having the structure of formula (I):

wherein m is 1; N is β-D-deoxyadenosine; X 1 and X 2 are each a phosphodiester linkage; and MO consists of the structure 5′-A E C S A E T E C S A E G E T E C S TGAU S AAGC S U S A S -3′ (SEQ ID NO: 58), wherein nucleosides not followed by a subscript are β-D-deoxyribonucleosides; nucleosides followed by a subscript “E” are 2′-MOE nucleosides; and nucleosides followed by a subscript “S” are S-cEt nucleosides.

2. The method of claim 1 , wherein the cell is in vitro.

3. The method of claim 1 , wherein the cell is in vivo.

4. The method of claim 1 , wherein the liver cell is a hepatocellular carcinoma cell.

5. The method of claim 1 , wherein following the contacting, the expression of SPG20 is increased.

6. The method of claim 1 , wherein following the contacting, the expression of Taf7 is increased.

7. The method of claim 1 , wherein following the contacting, the expression of Rnf176 is increased.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 14, 2024
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
To: REGULUS THERAPEUTICS INC.
Reel/Frame 067402/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: REGULUS THERAPEUTICS INC.
To: SANOFI
Reel/Frame 049344/0688 →
RELEASE OF SECURITY INTEREST Recorded Nov 7, 2018
From: OXFORD FINANCE LLC
To: REGULUS THERAPEUTICS INC.
Reel/Frame 047445/0286 →
SECURITY INTEREST Recorded Aug 8, 2018
From: REGULUS THERAPEUTICS INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT AND LENDER
Reel/Frame 046748/0561 →
Continuity (2)
Provisional Application 61895583 · Oct 25, 2013
Related Publication 20160333341A1 · Nov 17, 2016